- Home
- MGIH vs THAR Comparison
MGIH vs THAR Comparison
Compare MGIH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- THAR
- Stock Information
- Founded
- MGIH 1978
- THAR 2017
- Country
- MGIH Hong Kong
- THAR United States
- Employees
- MGIH N/A
- THAR N/A
- Industry
- MGIH Publishing
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- THAR Health Care
- Exchange
- MGIH Nasdaq
- THAR Nasdaq
- Market Cap
- MGIH 18.0M
- THAR 16.8M
- IPO Year
- MGIH 2023
- THAR 2022
- Fundamental
- Price
- MGIH $2.44
- THAR $2.66
- Analyst Decision
- MGIH
- THAR Strong Buy
- Analyst Count
- MGIH 0
- THAR 1
- Target Price
- MGIH N/A
- THAR $17.00
- AVG Volume (30 Days)
- MGIH 4.0M
- THAR 13.0M
- Earning Date
- MGIH 10-29-2025
- THAR 11-06-2025
- Dividend Yield
- MGIH N/A
- THAR N/A
- EPS Growth
- MGIH N/A
- THAR N/A
- EPS
- MGIH N/A
- THAR N/A
- Revenue
- MGIH $28,866,993.00
- THAR N/A
- Revenue This Year
- MGIH N/A
- THAR N/A
- Revenue Next Year
- MGIH N/A
- THAR N/A
- P/E Ratio
- MGIH N/A
- THAR N/A
- Revenue Growth
- MGIH N/A
- THAR N/A
- 52 Week Low
- MGIH $1.34
- THAR $0.95
- 52 Week High
- MGIH $6.83
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- MGIH 57.77
- THAR 44.37
- Support Level
- MGIH $1.83
- THAR $2.54
- Resistance Level
- MGIH $2.87
- THAR $3.46
- Average True Range (ATR)
- MGIH 0.68
- THAR 0.61
- MACD
- MGIH 0.05
- THAR -0.28
- Stochastic Oscillator
- MGIH 27.05
- THAR 2.55
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.